N83.31
Acquired atrophy of ovary
Clinical Classification Guidelines
Medical Intelligence & Overview
Acquired atrophy of the ovary, classified under ICD-10 code N83.31, refers to the gradual shrinking or loss of function of the ovary that occurs after birth. Unlike congenital ovarian conditions, this type of atrophy develops over time and can affect women at various stages of life. The condition might influence hormonal balance, reproductive health, and overall well-being, making awareness and understanding important. This article provides a comprehensive overview of the causes, symptoms, diagnosis, and potential management options associated with acquired ovarian atrophy, aiding patients and caregivers in better understanding this condition.
Causes & Symptoms
Clinical Causes: Aging naturally leads to a decline in ovarian tissue and function. Ovarian surgery or procedures damaging ovarian tissue. Chemotherapy or radiation therapy affecting ovarian health. Autoimmune disorders where the body's immune system targets ovarian tissue. Hormonal imbalances or prolonged hormonal therapies. Infections affecting the ovaries, such as pelvic inflammatory disease. Genetic conditions or predispositions impacting ovarian health. Chronic illnesses or health conditions that influence hormonal regulation.
Key Symptoms: Irregular or absent menstrual cycles (amenorrhea). Infertility or difficulty conceiving. Symptoms of hormonal imbalance such as hot flashes or night sweats. Vaginal dryness or discomfort during sexual activity. Decreased libido or sexual function. Bone density loss leading to osteoporosis over time. Possible abdominal or pelvic discomfort, although less common. Mood swings or psychological effects related to hormonal changes.
Diagnostic & Treatment
Diagnosis Path: The diagnosis of acquired ovarian atrophy involves a combination of medical history, physical examination, and a series of specialized tests. Imaging techniques such as ultrasound scans can assess ovarian size and structure. Blood tests measure hormone levels, including estrogen, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), to evaluate ovarian function. Sometimes, additional tests like hormone stimulation tests or ovarian biopsy may be performed to rule out other conditions. These assessments help determine the extent of ovarian tissue loss and guide appropriate management.
Treatment Protocols: Management of acquired ovarian atrophy focuses on alleviating symptoms and addressing associated health risks. Treatment options include hormone replacement therapy (HRT) to compensate for decreased estrogen levels, thereby reducing menopausal symptoms and preventing osteoporosis. Lifestyle modifications, such as a balanced diet and regular exercise, support overall health. Fertility options and counseling may be explored for women wishing to conceive. Regular monitoring and follow-up are essential to manage long-term health effects like bone density loss and cardiovascular risks. It is important to consult healthcare professionals experienced in managing ovarian and hormonal disorders to develop a personalized treatment plan.
Clinical Advice & FAQs
Billing Guidance
Is N83.31 a billable ICD-10 code?
Yes, N83.31 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report N83.31?
Clinical documentation must specify the nature of Acquired atrophy of ovary and any associated comorbidities for accurate reporting.
Cite this Clinical Reference